Table 3.

Efficacy of third-generation EGFR TKIs in EGFR T790M-positive NSCLC patients

Drug	Trial	Patients (N)	Dose	ORR T790M	PFS (mo.)
Osimertinib	AURA phase I [92]	Total: 253 T790M(+): 138	20-240 mg QD	T790M(+): 61% T790M(−): 21%	T790M(+): 9.6 T790M(−): 2.8
	AURA phase I T790M(+)	63	80 mg QD	71%	9.7
	AURA phase II	210	80 mg QD	70%	9.9
	AURA phase II extension [132]	411	80 mg QD	62%	12.3
	AURA phase III [84]	416 -Osimertinib arm: 279 -Chemotherapy arm: 140		71% 31% Odds ratio:5.39 (95% CI: 3.47–8.48)	10.1 4.4 HR: 0.30 (95% CI: 0.23–0.41)
Rociletinib	TIGER-X phase I/II [98]	Total: 69 T790M(+): 51	500, 625 or 750 mg bid	45%	T790M(+): 9.6 T790M(−): 2.8
Olmutinib	HM-EMSI-101 phase I/II T790M(+) [133]	76	800 mg QD	62%	6.9
ASP8273	NCT02113813 phase I/II [134]	Total: 63 T790M(+): 58	300 mg QD	29%	6.8
Nazartinib	NCT02108964 phase I/II [105]	152	75-350 mg QD	46.9%	9.7
Avitinib (AC0010)	NCT02330367 phase I/II [106]	136	50-350 mg QD	44%